ProShares UltraShort NASDAQ Biotechnology (BIS) price, chart and fund profile
Price chart
Fund profile
BIS provides -2x exposure to a market-cap-weighted index of biotechnology and pharmaceutical companies listed on the NASDAQ.
- Issuer
- ProShare Advisors
- Industry
- Healthcare
- Inception
- Apr 7, 2010
- Expense ratio
- 0.95%
- Net asset value
- $11.32
- NAV as of
- Aug 28, 2026
- Leverage
- 2×
- Fund page
- www.proshares.com↗
Frequently asked questions
What is ProShares UltraShort NASDAQ Biotechnology (BIS)?
BIS provides -2x exposure to a market-cap-weighted index of biotechnology and pharmaceutical companies listed on the NASDAQ.
What is BIS's expense ratio?
ProShares UltraShort NASDAQ Biotechnology charges an annual expense ratio of 0.95%. The fund is issued by ProShare Advisors.
How large is BIS?
ProShares UltraShort NASDAQ Biotechnology manages $1.9M in assets and has traded since Apr 7, 2010.
How do I buy shares of ProShares UltraShort NASDAQ Biotechnology (BIS)?
BIS trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web dashboard at portal.lighthorse.io, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.
Quotes and charts are not real-time and must not be relied on for trade decisions or valuation.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.